Innate lymphoid cells in intestinal cancer development

Mantovani, 2008, Cancer-related inflammation, Nature, 454, 436, 10.1038/nature07205 Mattner, 2017, Friend or foe? The ambiguous role of innate lymphoid cells in Cancer development, Trends Immunol., 38, 29, 10.1016/j.it.2016.10.004 Chiossone, 2018, Natural killer cells and other innate lymphoid cells in cancer, Nat. Rev. Immunol., 18, 671, 10.1038/s41577-018-0061-z van Beek, 2016, Innate lymphoid cells in tumor immunity, Biomedicines, 4, 10.3390/biomedicines4010007 Vivier, 2018, Innate lymphoid cells: 10 years on, Cell, 174, 1054, 10.1016/j.cell.2018.07.017 Klose, 2016, Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis, Nat. Immunol., 17, 765, 10.1038/ni.3489 Vivier, 2012, Targeting natural killer cells and natural killer T cells in cancer, Nat. Rev. Immunol., 12, 239, 10.1038/nri3174 Castriconi, 2018, Molecular mechanisms directing migration and retention of natural killer cells in human tissues, Front. Immunol., 9, 2324, 10.3389/fimmu.2018.02324 Hammer, 2018, Natural killer cell specificity for viral infections, Nat. Immunol., 19, 800, 10.1038/s41590-018-0163-6 Klose, 2014, Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages, Cell, 157, 340, 10.1016/j.cell.2014.03.030 Bernink, 2013, Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues, Nat. Immunol., 14, 221, 10.1038/ni.2534 Fuchs, 2013, Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells, Immunity, 38, 769, 10.1016/j.immuni.2013.02.010 Lim, 2018, ILC-poiesis: Ensuring tissue ILC differentiation at the right place and time, Eur. J. Immunol. Daussy, 2014, T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow, J. Exp. Med., 211, 563, 10.1084/jem.20131560 Gordon, 2012, The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation, Immunity, 36, 55, 10.1016/j.immuni.2011.11.016 Moro, 2010, Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells, Nature, 463, 540, 10.1038/nature08636 Neill, 2010, Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity, Nature, 464, 1367, 10.1038/nature08900 Price, 2010, Systemically dispersed innate IL-13-expressing cells in type 2 immunity, Proc. Natl. Acad. Sci. U. S. A., 107, 11489, 10.1073/pnas.1003988107 Wilhelm, 2011, An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation, Nat. Immunol., 12, 1071, 10.1038/ni.2133 Halim, 2012, Retinoic-acid-receptor-related orphan nuclear receptor alpha is required for natural helper cell development and allergic inflammation, Immunity, 37, 463, 10.1016/j.immuni.2012.06.012 Hoyler, 2012, The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells, Immunity, 37, 634, 10.1016/j.immuni.2012.06.020 Wong, 2012, Transcription factor RORalpha is critical for nuocyte development, Nat. Immunol., 13, 229, 10.1038/ni.2208 Kindermann, 2018, ILC2s in infectious diseases and organ-specific fibrosis, Semin. Immunopathol., 10.1007/s00281-018-0677-x Monticelli, 2011, Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus, Nat. Immunol., 12, 1045, 10.1038/ni.2131 Molofsky, 2013, Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages, J. Exp. Med., 210, 535, 10.1084/jem.20121964 Ealey, 2017, Are ILC2s jekyll and Hyde in airway inflammation?, Immunol. Rev., 278, 207, 10.1111/imr.12547 Barlow, 2014, Type-2 innate lymphoid cells in human allergic disease, Curr. Opin. Allergy Clin. Immunol., 14, 397, 10.1097/ACI.0000000000000090 Lambrecht, 2015, The immunology of asthma, Nat. Immunol., 16, 45, 10.1038/ni.3049 Spits, 2013, Innate lymphoid cells--a proposal for uniform nomenclature, Nat. Rev. Immunol., 13, 145, 10.1038/nri3365 Mortha, 2014, Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis, Science, 343, 1249288, 10.1126/science.1249288 Nussbaum, 2017, Tissue microenvironment dictates the fate and tumor-suppressive function of type 3 ILCs, J. Exp. Med., 214, 2331, 10.1084/jem.20162031 Lim, 2017, Systemic human ILC precursors provide a substrate for tissue ILC differentiation, Cell, 168, 10.1016/j.cell.2017.02.021 Brenner, 2018, The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention, Br. J. Cancer, 119, 785, 10.1038/s41416-018-0264-x Bacolod, 2011, Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition, Ann. Surg. Oncol., 18, 3694, 10.1245/s10434-011-1615-5 Fearon, 1990, A genetic model for colorectal tumorigenesis, Cell, 61, 759, 10.1016/0092-8674(90)90186-I Watson, 2011, Colon cancer: a civilization disorder, Dig. Dis., 29, 222, 10.1159/000323926 Wang, 2017, Role of tumor microenvironment in tumorigenesis, J. Cancer, 8, 761, 10.7150/jca.17648 Garagnani, 2013, Colorectal cancer microenvironment: among nutrition, gut microbiota, inflammation and epigenetics, Curr. Pharm. Des., 19, 765, 10.2174/138161213804581981 Galon, 2007, The adaptive immunologic microenvironment in colorectal cancer: a novel perspective, Cancer Res., 67, 1883, 10.1158/0008-5472.CAN-06-4806 Mathonnet, 2014, Hallmarks in colorectal cancer: angiogenesis and cancer stem-like cells, World J. Gastroenterol., 20, 4189, 10.3748/wjg.v20.i15.4189 Crotti, 2017, Extracellular matrix and colorectal cancer: how surrounding microenvironment affects Cancer cell behavior?, J. Cell. Physiol., 232, 967, 10.1002/jcp.25658 Fantini, 2005, Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy, Expert Rev. Anticancer Ther., 5, 681, 10.1586/14737140.5.4.681 Guba, 2004, Vascular endothelial growth factor in colorectal cancer, Int. J. Colorectal Dis., 19, 510, 10.1007/s00384-003-0576-y Miyamoto, 2009, Potential for molecularly targeted therapy against epidermal growth factor receptor ligands, Anticancer Res., 29, 823 Busser, 2011, The multiple roles of amphiregulin in human cancer, Biochim. Biophys. Acta, 1816, 119 Markman, 2015, Impact of the immune system and immunotherapy in colorectal cancer, J. Gastrointest. Oncol., 6, 208 Li, 2018, IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE2, J. Exp. Clin. Cancer Res., 37, 196, 10.1186/s13046-018-0839-7 Lotfi, 2009, Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells, J. Immunol., 183, 5023, 10.4049/jimmunol.0900504 Saraiva, 2018, New Insights Into the role of tissue eosinophils in the progression of colorectal cancer: a literature review, Acta Med. Port., 31, 329, 10.20344/amp.10112 Di Caro, 2013, Immune cells: plastic players along colorectal cancer progression, J. Cell. Mol. Med., 17, 1088, 10.1111/jcmm.12117 Atreya, 2008, Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies, Expert Rev. Anticancer Ther., 8, 561, 10.1586/14737140.8.4.561 Waldner, 2012, Interleukin-6–a key regulator of colorectal cancer development, Int. J. Biol. Sci., 8, 1248, 10.7150/ijbs.4614 De Simone, 2013, Role of TH17 cytokines in the control of colorectal cancer, Oncoimmunology, 2, e26617, 10.4161/onci.26617 De Simone, 2015, Th17-type cytokines, IL-6 and TNF-alpha synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth, Oncogene, 34, 3493, 10.1038/onc.2014.286 Hu, 2017, Increased expression of interleukin-23 associated with progression of colorectal cancer, J. Surg. Oncol., 115, 208, 10.1002/jso.24505 Pages, 1999, Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance, Int. J. Cancer, 84, 326, 10.1002/(SICI)1097-0215(19990621)84:3<326::AID-IJC22>3.0.CO;2-K Del Vecchio, 2007, Interleukin-12: biological properties and clinical application, Clin. Cancer Res., 13, 4677, 10.1158/1078-0432.CCR-07-0776 Bahri, 2015, IL-15 suppresses colitis-associated colon carcinogenesis by inducing antitumor immunity, Oncoimmunology, 4, e1002721, 10.1080/2162402X.2014.1002721 Mager, 2016, Cytokine-induced modulation of colorectal cancer, Front. Oncol., 6, 96, 10.3389/fonc.2016.00096 Katsios, 2013, Targeted therapy for colorectal cancer resistance to EGF receptor antibodies and new trends, Expert Rev. Gastroenterol. Hepatol., 7, 5, 10.1586/egh.12.60 Carrato, 2006, Anti-VEGF therapy: a new approach to colorectal cancer therapy, Expert Rev. Anticancer Ther., 6, 1385, 10.1586/14737140.6.10.1385 Hegde, 2008, Systemic and targeted therapy for advanced colon cancer, Expert Rev. Gastroenterol. Hepatol., 2, 135, 10.1586/17474124.2.1.135 Becker, 2015, The intestinal microbiota in inflammatory bowel disease, ILAR J., 56, 192, 10.1093/ilar/ilv030 Spits, 2016, NK cells and type 1 innate lymphoid cells: partners in host defense, Nat. Immunol., 17, 758, 10.1038/ni.3482 Fuchs, 2016, ILC1s in tissue inflammation and infection, Front. Immunol., 7, 104, 10.3389/fimmu.2016.00104 Kim, 2016, Migration and tissue tropism of innate lymphoid cells, Trends Immunol., 37, 68, 10.1016/j.it.2015.11.003 Gil-Cruz, 2016, Fibroblastic reticular cells regulate intestinal inflammation via IL-15-mediated control of group 1 ILCs, Nat. Immunol., 17, 1388, 10.1038/ni.3566 Abt, 2015, Innate immune defenses mediated by two ILC subsets are critical for protection against acute Clostridium difficile infection, Cell Host Microbe, 18, 27, 10.1016/j.chom.2015.06.011 Li, 2018, Innate lymphoid cells in inflammatory bowel disease, Arch. Immunol. Ther. Exp. (Warsz), 66, 415, 10.1007/s00005-018-0519-5 Schmitz, 2016, The composition and differentiation potential of the duodenal intraepithelial innate lymphocyte compartment is altered in coeliac disease, Gut, 65, 1269, 10.1136/gutjnl-2014-308153 Marafini, 2015, TNF-alpha producing innate lymphoid cells (ILCs) are increased in active celiac disease and contribute to promote intestinal atrophy in mice, PLoS One, 10, e0126291, 10.1371/journal.pone.0126291 Ricardo-Gonzalez, 2018, Tissue signals imprint ILC2 identity with anticipatory function, Nat. Immunol., 19, 1093, 10.1038/s41590-018-0201-4 Gury-BenAri, 2016, The spectrum and regulatory landscape of intestinal innate lymphoid cells are shaped by the microbiome, Cell, 166, 1231, 10.1016/j.cell.2016.07.043 von Moltke, 2016, Tuft-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit, Nature, 529, 221, 10.1038/nature16161 Nadjsombati, 2018, Detection of succinate by intestinal tuft cells triggers a type 2 innate immune circuit, Immunity, 49, 33, 10.1016/j.immuni.2018.06.016 Klose, 2017, The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation, Nature, 549, 282, 10.1038/nature23676 Cardoso, 2017, Neuronal regulation of type 2 innate lymphoid cells via neuromedin U, Nature, 549, 277, 10.1038/nature23469 Huang, 2015, IL-25-responsive, lineage-negative KLRG1(hi) cells are multipotential’ inflammatory’ type 2 innate lymphoid cells, Nat. Immunol., 16, 161, 10.1038/ni.3078 Huang, 2018, S1P-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense, Science, 359, 114, 10.1126/science.aam5809 Monticelli, 2015, IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions, Proc. Natl. Acad. Sci. U. S. A., 112, 10762, 10.1073/pnas.1509070112 Camelo, 2012, Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13, J. Gastroenterol., 47, 1198, 10.1007/s00535-012-0591-2 Zhong, 2018, Lymphoid tissue inducer-A divergent member of the ILC family, Cytokine Growth Factor Rev., 42, 5, 10.1016/j.cytogfr.2018.02.004 Coccia, 2012, IL-1beta mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells, J. Exp. Med., 209, 1595, 10.1084/jem.20111453 Zheng, 2008, Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens, Nat. Med., 14, 282, 10.1038/nm1720 Lindemans, 2015, Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration, Nature, 528, 560, 10.1038/nature16460 Pickert, 2009, STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing, J. Exp. Med., 206, 1465, 10.1084/jem.20082683 Wittkopf, 2015, Activation of intestinal epithelial Stat3 orchestrates tissue defense during gastrointestinal infection, PLoS One, 10, e0118401, 10.1371/journal.pone.0118401 Goto, 2014, Innate lymphoid cells regulate intestinal epithelial cell glycosylation, Science, 345, 1254009, 10.1126/science.1254009 Gladiator, 2013, Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection, J. Immunol., 190, 521, 10.4049/jimmunol.1202924 Munoz, 2009, Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17, J. Exp. Med., 206, 3047, 10.1084/jem.20090900 Hepworth, 2013, Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria, Nature, 498, 113, 10.1038/nature12240 Magri, 2014, Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells, Nat. Immunol., 15, 354, 10.1038/ni.2830 Buonocore, 2010, Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology, Nature, 464, 1371, 10.1038/nature08949 Geremia, 2011, IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease, J. Exp. Med., 208, 1127, 10.1084/jem.20101712 Klose, 2013, A T-bet gradient controls the fate and function of CCR6-RORgammat+ innate lymphoid cells, Nature, 494, 261, 10.1038/nature11813 Morvan, 2016, NK cells and cancer: you can teach innate cells new tricks, Nat. Rev. Cancer, 16, 7, 10.1038/nrc.2015.5 Vacca, 2018, Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes?, Immunol. Lett., 201, 14, 10.1016/j.imlet.2018.11.004 Tallerico, 2013, Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules, J. Immunol., 190, 2381, 10.4049/jimmunol.1201542 Pernot, 2014, Colorectal cancer and immunity: what we know and perspectives, World J. Gastroenterol., 20, 3738, 10.3748/wjg.v20.i14.3738 Tartter, 1987, The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer, Arch. Surg., 122, 1264, 10.1001/archsurg.1987.01400230050009 Rocca, 2013, Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients, Innate Immun., 19, 76, 10.1177/1753425912453187 Jobin, 2017, Association between natural killer cell activity and colorectal cancer in high-risk subjects undergoing colonoscopy, Gastroenterology, 153, 980, 10.1053/j.gastro.2017.06.009 Narai, 2002, Significance of transforming growth factor beta1 as a new tumor marker for colorectal cancer, Int. J. Cancer, 97, 508, 10.1002/ijc.1631 Otegbeye, 2018, Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models, PLoS One, 13, e0191358, 10.1371/journal.pone.0191358 Morris, 2015, Anti-G-CSF treatment induces protective tumor immunity in mouse colon cancer by promoting protective NK cell, macrophage and T cell responses, Oncotarget, 6, 22338, 10.18632/oncotarget.4169 Schlahsa, 2011, Granulocyte-colony-stimulatory factor: a strong inhibitor of natural killer cell function, Transfusion, 51, 293, 10.1111/j.1537-2995.2010.02820.x Bruno, 2018, Angiogenin and the MMP9-TIMP2 axis are up-regulated in proangiogenic, decidual NK-like cells from patients with colorectal cancer, FASEB J., 32, 5365, 10.1096/fj.201701103R Halama, 2011, Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines, Clin. Cancer Res., 17, 678, 10.1158/1078-0432.CCR-10-2173 Simoni, 2017, Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency, Immunity, 46, 148, 10.1016/j.immuni.2016.11.005 Wang, 2016, Reduced expression of galectin-9 contributes to a poor outcome in colon cancer by inhibiting NK cell chemotaxis partially through the Rho/ROCK1 signaling pathway, PLoS One, 11, e0152599, 10.1371/journal.pone.0152599 Ishikawa, 2018, Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer, Int. J. Cancer, 142, 2599, 10.1002/ijc.31285 Veluchamy, 2017, In vivo efficacy of umbilical cord blood stem cell-derived NK cells in the treatment of metastatic colorectal cancer, Front. Immunol., 8, 87, 10.3389/fimmu.2017.00087 Veluchamy, 2016, Combination of NK cells and cetuximab to enhance anti-tumor responses in RAS mutant metastatic colorectal cancer, PLoS One, 11, e0157830, 10.1371/journal.pone.0157830 Oppenheim, 2014, Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy, Br. J. Cancer, 110, 1221, 10.1038/bjc.2014.35 Peluso, 2006, Interleukin-12 and Th1 immune response in Crohn’s disease: pathogenetic relevance and therapeutic implication, World J. Gastroenterol., 12, 5606, 10.3748/wjg.v12.i35.5606 Duchmann, 1997, Responses to self and non-self intestinal microflora in health and inflammatory bowel disease, Res. Immunol., 148, 589, 10.1016/S0923-2494(98)80154-5 Engelbertsen, 2017, Innate lymphoid cells in atherosclerosis, Eur. J. Pharmacol., 816, 32, 10.1016/j.ejphar.2017.04.030 Kamada, 2008, Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis, J. Clin. Invest., 118, 2269 Glover, 2011, IFN-gamma attenuates hypoxia-inducible factor (HIF) activity in intestinal epithelial cells through transcriptional repression of HIF-1beta, J. Immunol., 186, 1790, 10.4049/jimmunol.1001442 Eriguchi, 2018, Essential role of IFN-gamma in T cell-associated intestinal inflammation, JCI Insight, 3, 10.1172/jci.insight.121886 Danese, 2013, Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future, Aliment. Pharmacol. Ther., 37, 855, 10.1111/apt.12284 Lopetuso, 2017, Can we predict the efficacy of anti-TNF-alpha agents?, Int. J. Mol. Sci., 18, 10.3390/ijms18091973 Bertazza, 2010, The dual role of tumor necrosis factor (TNF) in cancer biology, Curr. Med. Chem., 17, 3337, 10.2174/092986710793176339 Wajant, 2009, The role of TNF in cancer, Results Probl. Cell Differ., 49, 1, 10.1007/400_2008_26 Popivanova, 2008, Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis, J. Clin. Invest., 118, 560 Rizzo, 2014, Smad7 induces plasticity in tumor-infiltrating Th17 cells and enables TNF-alpha-mediated killing of colorectal cancer cells, Carcinogenesis, 35, 1536, 10.1093/carcin/bgu027 Chevalier, 2017, ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence, J. Clin. Invest., 127, 2916, 10.1172/JCI89717 Trabanelli, 2017, Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis, Nat. Commun., 8, 593, 10.1038/s41467-017-00678-2 Bie, 2014, Polarization of ILC2s in peripheral blood might contribute to immunosuppressive microenvironment in patients with gastric cancer, J. Immunol. Res., 2014, 923135, 10.1155/2014/923135 Forkel, 2018, Distinct alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established Crohn’s disease and ulcerative colitis, J. Crohns Colitis Heller, 2005, Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution, Gastroenterology, 129, 550, 10.1016/j.gastro.2005.05.002 Fuss, 1996, Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5, J. Immunol., 157, 1261, 10.4049/jimmunol.157.3.1261 Popp, 2017, Rectal delivery of a DNAzyme that specifically blocks the transcription factor GATA3 and reduces colitis in mice, Gastroenterology, 152, 176, 10.1053/j.gastro.2016.09.005 Gerlach, 2014, TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells, Nat. Immunol., 15, 676, 10.1038/ni.2920 Barderas, 2012, High expression of IL-13 receptor alpha2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis, Cancer Res., 72, 2780, 10.1158/0008-5472.CAN-11-4090 Zaiss, 2013, Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor, Immunity, 38, 275, 10.1016/j.immuni.2012.09.023 Mertz, 2016, The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice, OncoImmunology, 5, e1062966, 10.1080/2162402X.2015.1062966 Maywald, 2015, IL-33 activates tumor stroma to promote intestinal polyposis, Proc. Natl. Acad. Sci. U. S. A., 112, E2487, 10.1073/pnas.1422445112 O’Donnell, 2015, An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer, Br. J. Cancer, 114, 37, 10.1038/bjc.2015.433 Malik, 2016, IL-33 regulates the IgA-microbiota axis to restrain IL-1alpha-dependent colitis and tumorigenesis, J. Clin. Invest., 126, 4469, 10.1172/JCI88625 Jin, 2018, IL-33 Released in the Liver Inhibits Tumor Growth via Promotion of CD4+ and CD8+ T Cell Responses in Hepatocellular Carcinoma, J. Immunol., 201, 3770, 10.4049/jimmunol.1800627 Bonilla, 2012, The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses, Science, 335, 984, 10.1126/science.1215418 Penny, 2018, Orchestration of intestinal homeostasis and tolerance by group 3 innate lymphoid cells, Semin. Immunopathol., 40, 357, 10.1007/s00281-018-0687-8 Neurath, 2014, Cytokines in inflammatory bowel disease, Nat. Rev. Immunol., 14, 329, 10.1038/nri3661 Langowski, 2006, IL-23 promotes tumour incidence and growth, Nature, 442, 461, 10.1038/nature04808 Grivennikov, 2012, Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth, Nature, 491, 254, 10.1038/nature11465 Chan, 2014, Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells, Mucosal Immunol., 7, 842, 10.1038/mi.2013.101 Kirchberger, 2013, Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model, J. Exp. Med., 210, 917, 10.1084/jem.20122308 Huber, 2012, IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine, Nature, 491, 259, 10.1038/nature11535 Bollrath, 2009, gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis, Cancer Cell, 15, 91, 10.1016/j.ccr.2009.01.002 Bergmann, 2017, Card9-dependent IL-1beta regulates IL-22 production from group 3 innate lymphoid cells and promotes colitis-associated cancer, Eur. J. Immunol., 47, 1342, 10.1002/eji.201646765 Thompson, 2010, Interleukin-22 genetic polymorphisms and risk of colon cancer, Cancer Causes Control, 21, 1165, 10.1007/s10552-010-9542-5 Carrega, 2015, NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures, Nat. Commun., 6, 8280, 10.1038/ncomms9280 Eisenring, 2010, IL-12 initiates tumor rejection via lymphoid tissue–inducer cells bearing the natural cytotoxicity receptor NKp46, Nat. Immunol., 11, 1030, 10.1038/ni.1947